Wellington Management Group LLP Crinetics Pharmaceuticals, Inc. Transaction History

Wellington Management Group LLP

$503 Billion
Q1 2025

A detailed history of Wellington Management Group LLP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Wellington Management Group LLP holds 6,891,397 shares of CRNX stock, worth $196 Million. This represents 0.05% of its overall portfolio holdings.

Number of Shares

6,891,397

Holding current value

$196 Million

% of portfolio

0.05%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 13, 2025	BUY	$32.3 - $53.15 $223 Million - $366 Million	6,891,397 New	6,891,397 $231 Million
Q4 2024 Feb 12, 2025	BUY	$50.66 - $60.69 $126 Million - $151 Million	2,490,876 Added 55.85%	6,950,567 $355 Million
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $7.04 Million - $8.84 Million	-160,722 Reduced 3.48%	4,459,691 $228 Million
Q2 2024 Aug 13, 2024	BUY	$42.12 - $51.91 $69.4 Million - $85.6 Million	1,648,831 Added 55.49%	4,620,413 $207 Million
Q1 2024 May 15, 2024	BUY	$34.76 - $46.81 $103 Million - $139 Million	2,971,582 New	2,971,582 $139 Million
Q4 2023 Feb 12, 2024	BUY	$25.62 - $37.07 $83.1 Million - $120 Million	3,245,105 New	3,245,105 $115 Million
Q3 2023 Nov 14, 2023	BUY	$15.97 - $30.59 $615,212 - $1.18 Million	38,523 Added 1.07%	3,640,235 $108 Million
Q2 2023 Aug 14, 2023	SELL	$15.73 - $23.6 $531,894 - $798,010	-33,814 Reduced 0.93%	3,601,712 $64.9 Million
Q1 2023 May 12, 2023	BUY	$15.31 - $21.1 $12.7 Million - $17.5 Million	831,041 Added 29.63%	3,635,526 $58.4 Million
Q4 2022 Feb 13, 2023	BUY	$15.49 - $19.05 $2.66 Million - $3.27 Million	171,474 Added 6.51%	2,804,485 $51.3 Million
Q3 2022 Nov 14, 2022	BUY	$18.11 - $22.37 $14.7 Million - $18.1 Million	809,413 Added 44.39%	2,633,011 $51.7 Million
Q2 2022 Aug 15, 2022	BUY	$16.49 - $27.64 $13.1 Million - $22 Million	794,234 Added 77.16%	1,823,598 $34 Million
Q1 2022 May 16, 2022	SELL	$17.15 - $28.31 $701,572 - $1.16 Million	-40,908 Reduced 3.82%	1,029,364 $22.6 Million
Q4 2021 Feb 11, 2022	BUY	$19.35 - $28.41 $3.04 Million - $4.47 Million	157,201 Added 17.22%	1,070,272 $30.4 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $2.83 Million - $4.23 Million	167,684 Added 22.5%	913,071 $19.2 Million
Q2 2021 Aug 16, 2021	BUY	$15.9 - $21.15 $3.07 Million - $4.09 Million	193,220 Added 34.99%	745,387 $14.1 Million
Q1 2021 May 17, 2021	SELL	$13.3 - $17.55 $59,424 - $78,413	-4,468 Reduced 0.8%	552,167 $8.44 Million
Q4 2020 Feb 12, 2021	BUY	$12.08 - $17.46 $1.44 Million - $2.08 Million	118,879 Added 27.16%	556,635 $7.85 Million
Q3 2020 Nov 16, 2020	BUY	$13.62 - $17.66 $1.72 Million - $2.23 Million	126,475 Added 40.63%	437,756 $6.86 Million
Q2 2020 Aug 14, 2020	BUY	$13.04 - $23.23 $4.06 Million - $7.23 Million	311,281 New	311,281 $5.45 Million

Others Institutions Holding CRNX

# of Institutions

230

Shares Held

86.6M

Call Options Held

40K

Put Options Held

162K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $1.53B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wellington Management Group LLP, based on Form 13F filings with the SEC.

News

Stay updated on Wellington Management Group LLP with notifications on news.

Account

Wellington Management Group LLP Crinetics Pharmaceuticals, Inc. Transaction History